Hypersexuality in men with prolactinomas treated with dopamine agonists

被引：0
|
作者：
Irina Bancos
Todd B. Nippoldt
Dana Erickson
机构：
[1] Metabolism and Nutrition,Division of Endocrinology
[2] Mayo Clinic,undefined
来源：
Endocrine | 2017年 / 56卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：456 / 457
页数：1
相关论文
共 50 条
  • [21] Experience in the use of dopamine agonists in prolactinomas in a third level hospital
    Blanquez Martinez, David
    Hayon Ponce, Maria
    Caballero Romero, Alvaro
    Nieto Gomez, Pelayo
    Diaz Villamarin, Xando
    Garcia Fernandez, Cristina
    Cabeza Barrera, Jose
    Davila Fajardo, Cristina
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (01) : 301 - 301
  • [22] Proportion and predictors of Hypogonadism Recovery in Men with Macroprolactinomas treated with dopamine agonists
    Al Dahmani, Khaled M.
    Almalki, Mussa H.
    Ekhzaimy, Aishah
    Aziz, Faisal
    Bashier, Alaaeldin
    Mahzari, Moeber M.
    Beshyah, Salem A.
    PITUITARY, 2022, 25 (04) : 658 - 666
  • [23] Proportion and predictors of Hypogonadism Recovery in Men with Macroprolactinomas treated with dopamine agonists
    Khaled M Al Dahmani
    Mussa H. Almalki
    Aishah Ekhzaimy
    Faisal Aziz
    Alaaeldin Bashier
    Moeber M. Mahzari
    Salem A. Beshyah
    Pituitary, 2022, 25 : 658 - 666
  • [24] Metabolic effects of dopamine-agonists treatment among patients with prolactinomas
    Kabootari, Maryam
    Shirmohammadli, Habibeh
    Golgiri, Fatemeh
    Mosalamiaghili, Seyedarad
    Khajavi, Alireza
    Akbari, Hamideh
    ENDOCRINE, 2023, 79 (03) : 537 - 544
  • [25] Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment
    Colao, A
    DiSarno, A
    Sarnacchiaro, F
    Ferone, D
    DiRenzo, G
    Merola, B
    Annunziato, L
    Lombardi, G
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (03): : 876 - 883
  • [26] CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas
    Leong, KS
    Foy, PM
    Swift, AC
    Atkin, SL
    Hadden, DR
    MacFarlane, IA
    CLINICAL ENDOCRINOLOGY, 2000, 52 (01) : 43 - 49
  • [27] Metabolic effects of dopamine-agonists treatment among patients with prolactinomas
    Maryam Kabootari
    Habibeh Shirmohammadli
    Fatemeh Golgiri
    Seyedarad Mosalamiaghili
    Alireza Khajavi
    Hamideh Akbari
    Endocrine, 2023, 79 : 537 - 544
  • [28] Determinants of Recurrent Hyperprolactinemia in Prolactinomas and Idiopatic Hyperprolactinemia after Dopamine Agonists Suspension
    Lau, Eva
    Oliveira, Joana Isabel
    Oliveira, Ana Isabel
    Freitas, Paula
    Vinha, Eduardo
    Carvalho, Davide
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [29] EFFECT OF THE PREOPERATIVE USE OF DOPAMINE AGONISTS IN THE POSTOPERATIVE COURSE OF PROLACTINOMAS: A SYSTEMATIC REVIEW
    Carija, Robert
    Tudor, Mario
    Vucina, Diana
    ENDOCRINE PRACTICE, 2014, 20 (01) : 70 - 74
  • [30] Surgical outcomes in hyporesponsive prolactinomas: Analysis of patients with resistance or intolerance to dopamine agonists
    Hamilton D.K.
    Vance M.L.
    Boulos P.T.
    Laws E.R.
    Pituitary, 2005, 8 (1) : 53 - 60
12345